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Abstract—Background: Electronic medical records (EMRs) are used in large healthcare centers 
to increase efficiency and accuracy of documentation. These databases may be utilized for 
clinical research or to describe clinical practices such as medication usage. Methods: We 
conducted a retrospective analysis of EMR data from a headache clinic to evaluate clinician 
prescription use and dosing patterns of topiramate. The study cohort comprised 4833 unique de-
identified records, which were used to determine topiramate dose and persistence of treatment. 
Results: Within the cohort, migraine was the most common headache diagnosis (n = 3753, 
77.7%), followed by tension-type headache (n = 338, 7.0%) and cluster or trigeminal autonomic 
cephalalgias (n = 287, 5.9%). Physicians prescribed topiramate more often for subjects with 
migraine and idiopathic intracranial hypertension (IIH) (p < 0.0001) than for those with other 
conditions, and more often for subjects with coexisting conditions including obesity, bipolar 
disorder, and depression. The most common maintenance dose of topiramate was 100 mg/day; 
however, approximately 15% of subjects received either less than 100 mg/day or more than 200 
mg/day.  More than a third of subjects were prescribed topiramate for more than 1 year, and 
subjects with a diagnosis of migraine were prescribed topiramate for a longer period of time than 
those without migraine. Conclusions: Findings from our study using EMR demonstrate that 
physicians use topiramate at many different doses and for many off-label indications. This 
analysis provided important insight into our patient populations and treatment patterns.  
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Introduction. Electronic Medical Records (EMRs) have the potential to improve clinical 
efficiency and documentation. Recently, health care providers have begun using EMRs for 
clinical research. Most large-scale retrospective observational studies conducted to date have 
been based on insurance claims data (e.g., prescriptions filled to determine commonly prescribed 
doses of a medication).1 EMRs vary widely in their structure, capacity, and extent of data 
capture. Analysis is most successful in evaluating objective data, such as lab results. Subjective 
or complex variables can be more challenging to measure and document. Results from clinical 
practice may vary tremendously compared with the results of clinical trials. EMRs do not solve 
all issues with documentation; they can help standardize documentation but do not prevent 
inaccuracies.2 Most EMRs in clinical practice are designed to increase the accuracy of billing, 
eliminate the need for dictation, improve communication of health information between 
clinicians, and prevent errors rather than for use as a research tool. 
Retrospective EMR analyses have yielded important findings that can affect clinical care, such as 
studies showing increased cardiovascular event rates with the use of rofecoxib.3 Other EMR 
studies have documented prevention of medication errors4 and demonstrated trends in treatment 
response that may lead to better practice. For instance, a recent EMR analysis demonstrated that 
antiepileptic usage in elderly patients has not changed significantly despite changes in clinical 
guidelines.5 EMR studies can also help determine compliance with treatment guidelines and 
demonstrate cost savings.6 The goal of this pilot study was to explore the utility of EMR as a 
clinical research tool through an evaluation of patient demographics, diagnoses, and topiramate 
use in a cohort of patients treated at a university-based headache specialty clinic. 
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Methods. This study was a retrospective analysis of de-identified, aggregate EMR data from the 
Jefferson Headache Center in Philadelphia, Pennsylvania. A waiver of authorization for use of 
personal health information and Institutional Review Board approval was obtained. 
The Jefferson Headache Center utilizes Centricity® Physician Office (formerly Logician) to 
document and maintain patients’ medical records. All unique records with an initial office visit 
from April 1, 2000 through June 30, 2006 were evaluated and categorized into two patient 
groups: those who had received at least one prescription order for topiramate during the study 
period, and those who had not. The no topiramate group included patients who were never 
prescribed topiramate, or whose prescription start and stop date occurred before the study period, 
had an order entered and removed the same day, or had only a single order with instructions to 
taper off topiramate. All records have a clinical date-time stamp that is independent of the 
physician or nurse user. There are no required fields; the EMR system and documentation are 
driven by clinical care. The patient identifiers are system-generated markers that maintain related 
records. Medical diagnoses were recoded using both the ICD-9-CM code and description. 
Conditions that might influence topiramate use were examined, including diabetes, hypertension, 
obesity, epilepsy, anxiety, depression, bipolar disorder, tremor, and fibromyalgia. 
To ascertain dose and length of time on topiramate, tables containing the medication description 
(product name, dose form, strength) and instructions for each patient were merged with tables of 
prescription quantities, refills, and associated medication order key. The type of prescription, 
date, and time that the prescription was written were used to remove duplicates, and all 
prescription reprints were deleted. When there were multiple prescriptions for the same order on 
the same date with different pill quantities, the latest timed orders were retained. Maintenance 
dose was defined as the daily dose ordered for the longest total period of time. The start date for 
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determining total persistence of treatment was the first order date. If a patient had a documented 
stop date, it was used as the end date, and no further calculation was done. In instances where a 
patient did not have a documented stop date, the end date was calculated based on the last 
prescription date plus the pill supply days. We assumed the medication was taken as directed. 
Statistical methods. Analyses were conducted on the entire study group (patients with and 
patients without a topiramate prescription order) and then separately within the group of patients 
with topiramate prescription orders. Descriptive statistics such as means, medians, and 
frequencies between groups were calculated for age, race, gender, marital status, diagnoses, 
number of office visits, and contact time. Significance was tested using the Pearson chi-square 
test for categorical outcomes; the t-test or Wilcoxon two-sample test were used for continuous 
outcomes. Variables with a time dimension, such as persistence on topiramate, were analyzed 
separately by year. Within the group of patients with topiramate prescription orders, medication 
usage was similarly explored based on diagnoses, such as migraine or cluster headache. Simple 
logistic regression was used to determine any associations between patient factors (such as 
diagnosis) and topiramate use.  Significance was assessed using the Wald Chi-squared statistic. 
No adjustments for multiplicity were made due to the exploratory nature of this study. Statistical 
analyses were done using SAS 9.1 (SAS Institute, Cary, NC). 
Results. We extracted 4833 unique records with an initial visit during the study period of April 
1, 2000 through June 30, 2006. Study demographics are summarized in Table 1; most patients 
were white, female, and married at the time of the study. Race, gender, and age were all 
significantly associated with a topiramate prescription order but these results were complicated 
by missing data. Race was a missing field for 376 patients and 122 had no listed martial status.  
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Subjects with a topiramate order were on average 2.65 years younger than nonusers (mean age ± 
SD: 39.30 ± 12.63 vs 41.95 ± 15.99, p < 0.001). 
 The median number of clinic visits was six, and the mean visit number per record was eight. 
Patients who received prescription orders for topiramate had a greater number of clinic visits, 
with a median of nine, compared with a median of three visits for those without a topiramate 
order (p < 0.001). Patients who received topiramate continued their care at the Jefferson 
Headache Center for longer than those who did not (median: 378.5 days vs 63 days; p < 0.001). 
Diagnoses. Patients evaluated at the Jefferson Headache Center were found to have diagnoses in 
22 different categories. Primary headaches were most common, and migraine was the most 
common headache type: migraine (n = 3753; 77.7%), tension-type headache (n = 338; 7.0%), 
and cluster or trigeminal autonomic cephalalgias (n = 287, 5.9%). Secondary headache 
diagnoses, either alone or in addition to a primary headache diagnosis, were common (n = 1413; 
29.2%) and included cervicalgia, post-traumatic headache, idiopathic intracranial hypertension 
(IIH), tumor, cerebrovascular accident, or aneurysm. A total of 2443 (50.5%) patients had 
multiple headache diagnoses. The most common diagnosis combinations were: chronic migraine 
and medication overuse headache (n = 558, 11.5%), migraine without aura and chronic migraine 
(n = 512, 10.6%), migraine with and without aura (n = 304, 6.3%), and migraine with aura and 
chronic migraine (n = 285, 5.9%).  
At the Jefferson Headache Clinic, most prescription orders for topiramate were for patients with 
a diagnosis of migraine. Physicians ordered topiramate more often for patients with a diagnosis 
of migraine or IIH and less often for patients with tension headache, cluster headache, or cranial 
neuralgias such as trigeminal neuralgia. Patients who were overweight or obese, had bipolar 
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disorder, depression, seizures, tremors, or fibromyalgia received a prescription order for 
topiramate more frequently than the rest of the patient cohort (Table 2).  
Dosing. Topiramate was prescribed at doses ranging from as low as 15 mg every other day to as 
high as 1600 mg per day. Figure 1 shows the distribution of 2192 patients who received a dose of 
topiramate, by the maintenance and maximum daily topiramate dose. Maintenance dose was 
defined as the dose prescribed for the longest period of time during the study. The most 
frequently prescribed maintenance dose was 100 mg/day (n = 750, 34.2%). Our findings also 
revealed that 329 (15.0%) patients were prescribed a maintenance dose less than 100 mg/day and 
332 (15.1%) patients were prescribed a maintenance dose greater than 200 mg per day. The 
median topiramate daily dose (125 mg) was the same in migraine and non-migraine patients. The 
median topiramate daily dose (100 mg) was not significantly different in patients with tension-
type headache than patients without a diagnosis of tension-type headache (125mg).   IIH was the 
only headache diagnosis for which the median maintenance daily dose was higher than those 
with all other headache diagnoses. (200 mg vs 125 mg; p = 0.0106). 
Many factors can influence the dosing of topiramate, including the headache diagnosis and 
coexisting medical conditions. Patients with a diagnosis of migraine, particularly chronic 
migraine, were significantly more likely to have a diagnosis of depression. Of the 3753 patients 
in the “All migraine” category, 1241 (33%) also had a diagnosis of depression (odds ratio [OR], 
1.21; 95% confidence interval [CI], 1.04 to 1.40; p = 0.0114), and of the 2265 patients in the 
“chronic migraine” category, 945 (41.7%) also had a diagnosis of depression (OR, 2.30; 95% CI, 
2.04 to 2.61; p = <0.001). Patients with depression taking topiramate (830 of 1554 patients, 
53.4%) received a higher median daily dose than patients without a diagnosis of depression (150 
mg vs 100 mg; p = 0.0272). On the other hand, patients with anxiety disorders who were 
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prescribed topiramate (505 of 1053 patients, 48.0%) received a lower median topiramate dose 
than patients without the diagnosis (100 mg vs 150 mg; p = 0.0372). One hundred and fifteen of 
158 (72.8%) patients with an overweight or obesity diagnosis were prescribed topiramate and 
received a higher median daily dose of topiramate compared with patients without a diagnosis of 
being overweight or obese, but this was not significant (150 mg vs 125 mg; p = 0.1583).  
Persistence of treatment. Persistence of topiramate treatment was similar whether computed by 
the period patients took topiramate, based on prescription order data or by projection from the 
amount of pills taken. Figure 2 shows the proportion of patients and the total time that patients 
took topiramate. More than one third of all patients took topiramate for more than 1 year. Of the 
2192 patients who received topiramate during the study period, 2098 had at least two orders or 
one order and a prescription, allowing a dimension of persistence on the drug to be calculated. 
Six hundred and eighty three of the 2098 (32.6%) patients had topiramate on their current 
medication list and had a prescription in the final 6 months of the study. In all years during the 
study period, most patients who received topiramate, had a diagnosis of migraine. During the 
entire study period (2000-2006), patients with migraine remained on topiramate an average of 
108 days longer than patients without migraine. Persistence was longer for patients with 
migraine who began therapy in the years 2001, 2003, 2004, and 2005 (p = 0.0349, 0.0192, 
0.0346, and 0.0144), and marginally so for patients who began taking topiramate in 2002 (p = 
0.0781), compared with patients without a diagnosis of migraine (table 3). 
Discussion. This study provides insight into the usefulness of EMR as a clinical research tool 
through an assessment of how practitioners at a university referral center used topiramate in 
everyday clinical practice for the treatment of patients with headache. Results indicate that 
clinicians at the headache center prescribe topiramate to treat many different types of headaches. 
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Topiramate is approved by the United States Food and Drug Administration (FDA) for the 
prevention of migraine in adults, so it is not surprising that physicians at the headache center had 
prescribed topiramate for nearly half of the patients in the study population. Patients who were 
younger, female, and white were more likely to have received topiramate, probably because 
these patients were more likely to have a diagnosis of migraine and chronic migraine than those 
in the no topiramate group. Providers were more likely to prescribe topiramate during treatment 
for patients with more clinic visits, possibly because the headache center’s physicians tend to 
prescribe topiramate more often for cases of refractory headache. Our EMR does not require 
physicians to distinguish between chronic and episodic migraine, and many patients have both a 
chronic and episodic diagnosis, as patients often improve or worsen with treatment. This makes 
it difficult to determine if different doses are needed for those with chronic migraine. 
In our study, topiramate was prescribed for uses that have not been approved by the FDA, such 
as IIH. Recent studies have shown topiramate to be effective for IIH.12,13 Many patients with 
secondary headaches, cluster headache, and cranial neuralgias also received topiramate. Some 
small studies have shown that topiramate can be helpful for patients with trigeminal 
neuralgia14,15 or cluster headache.16 Our study also indicates that topiramate was more likely to 
have been prescribed for patients with coexisting medical diagnoses such as depression, bipolar 
disorder, and obesity. This finding could be related to the fact that depression and bipolar 
disorder are co-morbid conditions in chronic migraine; while obesity has been implicated as a 
risk factor for developing chronic migraine.17 Physicians may also have prescribed topiramate 
with the hope of inducing weight loss in obese patients.  
The variability of the daily doses of topiramate in the study was notable. Physicians prescribed, 
on average, higher doses of topiramate for patients with chronic migraine or IIH. Clinical studies 
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to date have used daily doses of 200 mg or less for migraine prevention. In a study of patients 
with episodic migraine, topiramate 200 mg/day was no more effective than 100 mg/day.18 In 
contrast, a minority of patients seen at the Jefferson Headache Clinic received doses higher than 
200 mg/day, perhaps because they metabolized the medication more efficiently, were more 
resistant to medication-related side effects, and/or had conditions that were less responsive to 
usual treatment. Other patients received daily doses less than 100 mg, often for extended periods 
of time. Paresthesias, a common topiramate side effect, may be bothersome to anxious patients, 
and may explain why they tend to be on lower doses. The study emphasizes the importance of 
individualizing treatment.  
Headache classification and practice evolved over the specified study period, leading to an 
increasing tendency for physicians to enter more than one headache diagnosis into the EMR. For 
example, the diagnosis of transformed migraine was initially cited on the headache center’s 
custom list as “transformed migraine with and without rebound”, a combination of two distinct 
diagnoses. The diagnoses were eventually separated and, for the “with rebound” diagnosis 
segment, the nomenclature was changed to medication overuse headache to align with new 
diagnostic terminology. Moreover, many patients with a diagnosis of migraine received 
additional diagnoses, such as cervicalgia, tension headache, or cervical dystonia, to reflect these 
coexisting conditions and their possible contribution to the clinical presentation of the patient’s 
migraine disorder. This practice increased as billing documentation requirements became more 
rigorous. One issue related to this change in documentation is that multiple diagnoses make it 
difficult to determine the primary reason which motivated the patient to seek treatment; EMR 
does not require clinicians to list the most significant illness first. 
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Using EMR data for the various clinical analyses provided useful information regarding patient 
characteristics, diagnoses, coexisting medical conditions, and treatment patterns, but organizing 
and analyzing these data presented numerous challenges. Limitations in interpreting the results 
include the fact that most EMR systems are primarily used for billing and clinical practice 
documentation rather than research purposes. EMRs used for clinical practice purposes do not 
require the same degree of monitoring and visit-to-visit consistency that is usually required in 
traditionally designed clinical trials. The EMR analyzed in this study had no required fields, and 
important data fields basic to research, such as race or marital status, often had missing data. In 
clinical practice, an EMR with required fields places an added time burden on clinicians, but this 
lack of required data makes research more difficult. Although some patients follow up at regular 
intervals, others may visit the clinic more often when they are not doing well and only 
sporadically when they are feeling better. In addition, physicians and healthcare systems tend to 
vary in their documentation styles. For instance, because most patients at the Jefferson Headache 
Clinic are required to see a mental health provider, better availability of psychiatric diagnoses in 
the EMR would be expected. Many medical diagnoses were underrepresented because of the 
specialty focus of the clinicians at the headache center. Although patients fill out a questionnaire 
before their initial visit with a past medical history, a diagnosis is only listed in the EMR if a 
nurse or physician enters the diagnosis. The EMR does not automatically generate diagnoses 
based on data such as height and weight, so obesity in this cohort was greatly underdiagnosed 
due to fact that many providers did not enter the diagnosis in the EMR. Similarly, we believe that 
fibromyalgia, a co-morbid condition reportedly found in more than 20% of female patients with 
migraine, was likely underdiagnosed.19  
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The data in fields for medication and dosing were also often incomplete or difficult to analyze. 
For example, a prescription might have had unclear directions for administration, such as “taper 
as directed,” requiring assumptions to be made about the intended dose. Moreover, physicians 
may not have documented the dispensing of drug samples to patients, perhaps affecting the 
initial dose and persistence analyses. In addition, patients received multiple prescriptions at the 
same visit. For instance, a physician would prescribe a 1-month supply of medication with three 
refills, but the patient would subsequently request a 90-day prescription for mail order drug 
delivery, which led to entry of new prescription data into the EMR. Some repeat EMR order 
entries were obvious, but others required manual review of the EMR to determine the actual 
intended dose. Finally, we needed to make assumptions about patients who lapsed in their clinic 
treatment. Clinic policy is not to refill prescriptions without a visit within the year. 
Discontinuation was assumed, but manual review revealed that some patients who stopped 
taking topiramate did so because their headaches improved, they were planning to become 
pregnant, or they did not make a clinic visit for an extended period. Some patients continued to 
receive topiramate from an outside provider, and others stopped the medication only to resume it 
later. Additionally, the study end date placed a false stop time on those who received additional 
prescriptions.  
Another assumption was that patients took their medication as prescribed, but many patients fail 
to take prophylactic medication for adequate lengths of time. Based on data from pharmacy 
claims, more than half of patients discontinue migraine prophylactic treatment by two months. 
The rate of topiramate treatment persistence at 2 months in one study was 46.4%, and the 
treatment persistence of other common preventatives such as amitriptyline (34.1%) and 
divalproex sodium (42.7%) were even lower. 20 
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This pilot study extracted and analyzed data from the EMR system used at the Jefferson 
Headache Center. The consistency of staff and practice patterns within the Headache Center is 
believed to have strengthened this study’s findings. Although the results can be useful for 
examining practice patterns and treatment trends at the Jefferson Headache Center, they cannot 
be generalized to all medical or headache specialty practices because of variability in patient 
populations and local standards of care. Likewise, the utility of this clinical research method and 
its findings cannot be generalized to all EMR systems, because of wide variability in system 
structure and format. This research study required funding and extensive review to validate the 
findings and understand the discrepancies.  These are luxuries that are not available to the 
average office practice.  Dedicated effort and resources to understand the clinical information 
available in EMRs may be underestimated or underreported.  Overall, the utility of EMRs for 
research would be enhanced by the standardization of EMR system design. If standardized, 
EMRs could be a useful tool for evaluating patient populations, disease categories, treatment 
patterns, and clinical outcomes within and across healthcare systems or local geographic regions. 
With these insights, it might be possible to determine best practices as well as practices that 
require improvement and ongoing monitoring. Without standardization and forethought in the 
design or use of EMR systems, a number of limitations in the analysis of EMR data could have 
the consequence of producing clinical information and outcome assessments that are difficult to 
interpret and lack a reasonable level of confidence. 
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Table 1 Demographics 
Demographics  
Received topiramate 
(n = 2192) 
Did not receive topiramate 
(n = 2641) 
 
p value 
 
n % n % 
 
Race (n = 4457)      
White 1933 93.43 2185 91.50 <0.001# 
Non-white  136 * 6.57     203 ** 8.50  
* (Black 105, Hispanic 18, Native American 2, Asian 5, Other 6)  
** (Black 128, Hispanic 16, Native American 5, Asian 34, Other 20) 
Undetermined               376 
Gender       
Female 1763 80.43 1831 69.33 <0.001# 
Male 429 19.57 810 30.67  
Marital status (n = 4680)     
Married 1261 58.54 1409 55.78 0.0571 
Not married     893 *** 41.46       1117 *** 44.22  
*** (Separated 19, Divorced 113, Single 742, Other 2, Widowed 17) 
**** (Separated 23, Divorced 134, Single 886, Other 9, Widowed 65) 
Undetermined        122   
Age    
Mean ± SD 
Median 
Min, max 
39.30 ± 12.63 
39.83 
12.45, 86.34 
41.95 ± 15.99 
41.17 
13.31, 90.22 
<0.001† 
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#p values derived by the χ2 test.  
†p value derived by the t-test. 
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Table 2 Association of topiramate prescription by broad headache category and co-existing 
diagnoses 
 
Total 
number of 
patients 
Patients on 
topiramate 
(%) 
Odds 
ratio* 
95% 
Confidence 
Interval 
p value 
Diagnostic category      
Migraine 3753 1832 (48.8) 1.91 (1.66, 2.20) <0.0001 
Tension 338 103 (30.47) 0.51 (0.40, 0.64) <0.0001 
Cluster 269 100 (37.17) 0.70 (0.54, 0.90) NS 
Other primary and NOS 869 397 (45.68) 1.02 (0.88, 1.18) NS 
Secondary (post-traumatic and 
IIH excluded) 
1164 553 (47.51) 1.12 (0.98, 1.28) NS 
Post-traumatic 181 78 (43.09) 0.91 (0.67, 1.23) NS 
IIH  178 135 (75.84) 3.97 (2.80, 5.62) <0.0001 
Cranial neuralgias 161 56 (34.78) 0.63 (0.46, 0.88) 0.0066 
Co-existing diagnosis      
Diabetes 78 38 (48.72) 1.15 (0.73, 1.80) NS 
Overweight and obesity 158 115 (72.78) 3.34 (2.34, 4.77) <0.0001 
Anxiety and panic 1053 505 (47.96) 1.14 (1.00, 1.31) NS 
Bipolar 186 113 (60.75) 1.91 (1.42, 2.58) <0.0001 
Depression 1554 830 (53.41) 1.61 (1.43, 1.82) <0.0001 
Seizures 76 46 (60.53) 1.87 (1.17, 2.97) 0.0084 
Fibromyalgia 115 70 (60.87) 1.90 (1.30, 2.78) 0.0009 
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Tremors 51 34 (66.67) 2.43 (1.36. 4.37) 0.0029 
*Odds ratios were calculated using simple logistic regression, and p values are the associated p 
values from the Wald Chi square tests associated with those univariate models. 
IIH = idiopathic intracranial hypertension; NOS = not otherwise specified. 
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Table 3 Total persistence on topiramate during study period by year and migraine status 
Year Migraine status Number of patients 
Median number of days 
(min, max) 
p value* 
No 28 251.5 (28,2295) NS 
2000 
Yes 94 399.5 (26,2263)  
No 54 146 (14,1924) 0.0349 
2001 
Yes 215 300 (15,1927)  
No 46 259 (15,1480) NS 
2002 
Yes 299 388 (1,1639)  
No 55 212 (7,1214) 0.0192 
2003 
Yes 288 334 (10,1271)  
No 52 139.5 (27,844) 0.0346 
2004 
Yes 332 272.5 (30,899)  
No 70 166.5 (21,506) 0.0144 
2005 
Yes 369 212 (6,543)  
No 31 64 (19,163) NS 
2006 
Yes 164 90 (1,177)  
*p values derived by the Wilcoxon test. 
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Figure 1. Distribution of patients taking topiramate by maintenance and maximum daily dose. 
Maintenance dose is defined as the dose for the longest period of time during the study. All 
patients were included regardless of length of treatment. A total of 2192 patient records were 
evaluated. 
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Figure 2. Persistence on topiramate based on the period patients took topiramate or projection 
from the number of pills. Total number of patient records evaluated: study period, n = 2097; 
number of pills, n = 2098. 
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